Current status and future prospects of yellow fever vaccines

Andrew S. Beck, Alan Barrett

Research output: Contribution to journalArticle

19 Citations (Scopus)

Abstract

Yellow fever 17D vaccine is one of the oldest live-attenuated vaccines in current use that is recognized historically for its immunogenic and safe properties. These unique properties of 17D are presently exploited in rationally designed recombinant vaccines targeting not only flaviviral antigens but also other pathogens of public health concern. Several candidate vaccines based on 17D have advanced to human trials, and a chimeric recombinant Japanese encephalitis vaccine utilizing the 17D backbone has been licensed. The mechanism(s) of attenuation for 17D are poorly understood; however, recent insights from large in silico studies have indicated particular host genetic determinants contributing to the immune response to the vaccine, which presumably influences the considerable durability of protection, now in many cases considered to be lifelong. The very rare occurrence of severe adverse events for 17D is discussed, including a recent fatal case of vaccine-associated viscerotropic disease.

Original languageEnglish (US)
Pages (from-to)1479-1492
Number of pages14
JournalExpert Review of Vaccines
Volume14
Issue number11
DOIs
StatePublished - Nov 2 2015

Fingerprint

Yellow Fever Vaccine
Synthetic Vaccines
Vaccines
Japanese Encephalitis Vaccines
Attenuated Vaccines
Computer Simulation
Public Health
Antigens

Keywords

  • empiric
  • empiric vaccine
  • flavivirus
  • live-attenuated
  • primary seed
  • rational vaccine
  • recombinant vaccine
  • secondary seed
  • vaccine
  • viral diversity
  • yellow fever virus

ASJC Scopus subject areas

  • Immunology
  • Drug Discovery
  • Pharmacology
  • Molecular Medicine

Cite this

Current status and future prospects of yellow fever vaccines. / Beck, Andrew S.; Barrett, Alan.

In: Expert Review of Vaccines, Vol. 14, No. 11, 02.11.2015, p. 1479-1492.

Research output: Contribution to journalArticle

@article{ebcaf75f75884430be3e239ac350cf0e,
title = "Current status and future prospects of yellow fever vaccines",
abstract = "Yellow fever 17D vaccine is one of the oldest live-attenuated vaccines in current use that is recognized historically for its immunogenic and safe properties. These unique properties of 17D are presently exploited in rationally designed recombinant vaccines targeting not only flaviviral antigens but also other pathogens of public health concern. Several candidate vaccines based on 17D have advanced to human trials, and a chimeric recombinant Japanese encephalitis vaccine utilizing the 17D backbone has been licensed. The mechanism(s) of attenuation for 17D are poorly understood; however, recent insights from large in silico studies have indicated particular host genetic determinants contributing to the immune response to the vaccine, which presumably influences the considerable durability of protection, now in many cases considered to be lifelong. The very rare occurrence of severe adverse events for 17D is discussed, including a recent fatal case of vaccine-associated viscerotropic disease.",
keywords = "empiric, empiric vaccine, flavivirus, live-attenuated, primary seed, rational vaccine, recombinant vaccine, secondary seed, vaccine, viral diversity, yellow fever virus",
author = "Beck, {Andrew S.} and Alan Barrett",
year = "2015",
month = "11",
day = "2",
doi = "10.1586/14760584.2015.1083430",
language = "English (US)",
volume = "14",
pages = "1479--1492",
journal = "Expert Review of Vaccines",
issn = "1476-0584",
publisher = "Expert Reviews Ltd.",
number = "11",

}

TY - JOUR

T1 - Current status and future prospects of yellow fever vaccines

AU - Beck, Andrew S.

AU - Barrett, Alan

PY - 2015/11/2

Y1 - 2015/11/2

N2 - Yellow fever 17D vaccine is one of the oldest live-attenuated vaccines in current use that is recognized historically for its immunogenic and safe properties. These unique properties of 17D are presently exploited in rationally designed recombinant vaccines targeting not only flaviviral antigens but also other pathogens of public health concern. Several candidate vaccines based on 17D have advanced to human trials, and a chimeric recombinant Japanese encephalitis vaccine utilizing the 17D backbone has been licensed. The mechanism(s) of attenuation for 17D are poorly understood; however, recent insights from large in silico studies have indicated particular host genetic determinants contributing to the immune response to the vaccine, which presumably influences the considerable durability of protection, now in many cases considered to be lifelong. The very rare occurrence of severe adverse events for 17D is discussed, including a recent fatal case of vaccine-associated viscerotropic disease.

AB - Yellow fever 17D vaccine is one of the oldest live-attenuated vaccines in current use that is recognized historically for its immunogenic and safe properties. These unique properties of 17D are presently exploited in rationally designed recombinant vaccines targeting not only flaviviral antigens but also other pathogens of public health concern. Several candidate vaccines based on 17D have advanced to human trials, and a chimeric recombinant Japanese encephalitis vaccine utilizing the 17D backbone has been licensed. The mechanism(s) of attenuation for 17D are poorly understood; however, recent insights from large in silico studies have indicated particular host genetic determinants contributing to the immune response to the vaccine, which presumably influences the considerable durability of protection, now in many cases considered to be lifelong. The very rare occurrence of severe adverse events for 17D is discussed, including a recent fatal case of vaccine-associated viscerotropic disease.

KW - empiric

KW - empiric vaccine

KW - flavivirus

KW - live-attenuated

KW - primary seed

KW - rational vaccine

KW - recombinant vaccine

KW - secondary seed

KW - vaccine

KW - viral diversity

KW - yellow fever virus

UR - http://www.scopus.com/inward/record.url?scp=84945437519&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84945437519&partnerID=8YFLogxK

U2 - 10.1586/14760584.2015.1083430

DO - 10.1586/14760584.2015.1083430

M3 - Article

VL - 14

SP - 1479

EP - 1492

JO - Expert Review of Vaccines

JF - Expert Review of Vaccines

SN - 1476-0584

IS - 11

ER -